Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

HIV-1 Tat promotes astrocytic release of CCL2 through MMP/PAR-1 signaling.

Bozzelli PL, Yin T, Avdoshina V, Mocchetti I, Conant KE, Maguire-Zeiss KA.

Glia. 2019 Sep;67(9):1719-1729. doi: 10.1002/glia.23642. Epub 2019 May 23.

PMID:
31124192
2.

Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies.

Caplan IF, Maguire-Zeiss KA.

Front Pharmacol. 2018 May 4;9:417. doi: 10.3389/fphar.2018.00417. eCollection 2018. Review.

3.

Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons.

Winland CD, Welsh N, Sepulveda-Rodriguez A, Vicini S, Maguire-Zeiss KA.

Eur J Neurosci. 2017 Nov;46(9):2519-2533. doi: 10.1111/ejn.13711. Epub 2017 Oct 10.

4.

Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1.

Allen M, Ghosh S, Ahern GP, Villapol S, Maguire-Zeiss KA, Conant K.

Sci Rep. 2016 Oct 20;6:35497. doi: 10.1038/srep35497.

5.

Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders.

Daniele SG, Béraud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA.

Sci Signal. 2015 May 12;8(376):ra45. doi: 10.1126/scisignal.2005965.

6.

From student to steward: the Interdisciplinary Program in Neuroscience at Georgetown University as a case study in professional development during doctoral training.

Ullrich L, Dumanis SB, Evans TM, Jeannotte AM, Leonard C, Rozzi SJ, Taylor CM, Gale K, Kanwal JS, Maguire-Zeiss KA, Wolfe BB, Forcelli PA.

Med Educ Online. 2014 Jul 7;19:22623. doi: 10.3402/meo.v19.22623. eCollection 2014.

7.

The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Savolainen MH, Richie CT, Harvey BK, Männistö PT, Maguire-Zeiss KA, Myöhänen TT.

Neurobiol Dis. 2014 Aug;68:1-15. doi: 10.1016/j.nbd.2014.04.003. Epub 2014 Apr 16.

PMID:
24746855
8.

Isolation of cortical microglia with preserved immunophenotype and functionality from murine neonates.

Daniele SG, Edwards AA, Maguire-Zeiss KA.

J Vis Exp. 2014 Jan 30;(83):e51005. doi: 10.3791/51005.

9.

Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Huang L, Shimoji M, Wang J, Shah S, Kamila S, Biehl ER, Lim S, Chang A, Maguire-Zeiss KA, Su X, Federoff HJ.

Neurotherapeutics. 2013 Oct;10(4):840-51. doi: 10.1007/s13311-013-0208-3.

10.

Parkinson's disease.

Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA.

Subcell Biochem. 2012;65:389-455. doi: 10.1007/978-94-007-5416-4_16. Review.

11.

Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein.

Béraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, Federoff HJ, Shimoji M, Mhyre TR, Maguire-Zeiss KA.

J Neuroimmune Pharmacol. 2013 Mar;8(1):94-117. doi: 10.1007/s11481-012-9401-0. Epub 2012 Oct 10.

12.
13.

Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.

Béraud D, Maguire-Zeiss KA.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S17-20. doi: 10.1016/S1353-8020(11)70008-6. Review.

14.

α-Synuclein Alters Toll-Like Receptor Expression.

Béraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K, Chasovskikh S, Mhyre TR, Maguire-Zeiss KA.

Front Neurosci. 2011 Jun 29;5:80. doi: 10.3389/fnins.2011.00080. eCollection 2011.

15.

Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.

Feng LR, Maguire-Zeiss KA.

Neurotox Res. 2011 Nov;20(4):387-401. doi: 10.1007/s12640-011-9255-x. Epub 2011 Jul 7.

16.

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, Dawson TM.

Nat Med. 2010 Sep;16(9):998-1000. doi: 10.1038/nm.2199. Epub 2010 Aug 22.

17.

Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability.

Feng LR, Federoff HJ, Vicini S, Maguire-Zeiss KA.

Eur J Neurosci. 2010 Jul;32(1):10-7. doi: 10.1111/j.1460-9568.2010.07266.x. Epub 2010 Jun 14.

18.

Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease.

Maguire-Zeiss KA, Federoff HJ.

J Neural Transm (Vienna). 2010 Aug;117(8):1019-25. doi: 10.1007/s00702-010-0431-6. Epub 2010 Jun 12. Review.

PMID:
20549523
19.

Gene therapy in Parkinson's disease: rationale and current status.

Feng LR, Maguire-Zeiss KA.

CNS Drugs. 2010 Mar;24(3):177-92. doi: 10.2165/11533740-000000000-00000. Review.

20.

Mutant alpha-synuclein overexpression mediates early proinflammatory activity.

Su X, Federoff HJ, Maguire-Zeiss KA.

Neurotox Res. 2009 Oct;16(3):238-54. doi: 10.1007/s12640-009-9053-x. Epub 2009 Apr 28.

21.

Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases.

Maguire-Zeiss KA, Federoff HJ.

J Neuroimmune Pharmacol. 2009 Sep;4(3):298-308. doi: 10.1007/s11481-008-9133-3. Epub 2008 Oct 18. Review.

22.

alpha-Synuclein: a therapeutic target for Parkinson's disease?

Maguire-Zeiss KA.

Pharmacol Res. 2008 Nov-Dec;58(5-6):271-80. doi: 10.1016/j.phrs.2008.09.006. Epub 2008 Sep 16. Review.

23.

Gazing into the future: Parkinson's disease gene therapeutics to modify natural history.

Maguire-Zeiss KA, Mhyre TR, Federoff HJ.

Exp Neurol. 2008 Jan;209(1):101-13. Epub 2007 Oct 11. Review.

PMID:
18035353
24.

Synuclein activates microglia in a model of Parkinson's disease.

Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ.

Neurobiol Aging. 2008 Nov;29(11):1690-701. Epub 2007 May 29.

25.

Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.

Mhyre TR, Loy R, Tariot PN, Profenno LA, Maguire-Zeiss KA, Zhang D, Coleman PD, Federoff HJ.

Neurobiol Aging. 2008 Nov;29(11):1631-43. Epub 2007 May 22.

26.

Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.

Sortwell CE, Bowers WJ, Counts SE, Pitzer MR, Fleming MF, McGuire SO, Maguire-Zeiss KA, Federoff HJ, Collier TJ.

Brain Res. 2007 Feb 23;1134(1):33-44. Epub 2006 Dec 28.

27.

Identification of human alpha-synuclein specific single chain antibodies.

Maguire-Zeiss KA, Wang CI, Yehling E, Sullivan MA, Short DW, Su X, Gouzer G, Henricksen LA, Wuertzer CA, Federoff HJ.

Biochem Biophys Res Commun. 2006 Nov 3;349(4):1198-205. Epub 2006 Aug 30.

PMID:
16973126
28.

Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector.

Bowers WJ, Mastrangelo MA, Howard DF, Southerland HA, Maguire-Zeiss KA, Federoff HJ.

Mol Ther. 2006 Mar;13(3):580-8. Epub 2006 Jan 18.

29.

Novel gene therapeutic strategies for neurodegenerative diseases.

Maguire-Zeiss KA, Federoff HJ.

Ernst Schering Res Found Workshop. 2005;(53):147-71. Review.

PMID:
16315613
30.

Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?

Maguire-Zeiss KA, Short DW, Federoff HJ.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):18-23. Review.

PMID:
15790526
31.

Safety of viral vectors for neurological gene therapies.

Maguire-Zeiss KA, Federoff HJ.

Curr Opin Mol Ther. 2004 Oct;6(5):473-81. Review.

PMID:
15537048
32.

Convergent pathobiologic model of Parkinson's disease.

Maguire-Zeiss KA, Federoff HJ.

Ann N Y Acad Sci. 2003 Jun;991:152-66. Review.

PMID:
12846984
33.

Somatic mosaic approaches and the aging brain.

Maguire-Zeiss KA, Bowers WJ, Federoff HJ.

Neurobiol Aging. 2002 Sep-Oct;23(5):977-84. Review.

PMID:
12392799
34.

HSV vector-mediated gene delivery to the central nervous system.

Maguire-Zeiss KA, Bowers WJ, Federoff HJ.

Curr Opin Mol Ther. 2001 Oct;3(5):482-90. Review.

PMID:
11699893
35.

Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients.

Richfield EK, Maguire-Zeiss KA, Vonkeman HE, Voorn P.

Ann Neurol. 1995 Dec;38(6):852-61.

PMID:
8526457
36.

Calbindin D28k mRNA in hippocampus, superior temporal gyrus and cerebellum: comparison between control and Alzheimer disease subjects.

Maguire-Zeiss KA, Li ZW, Shimoda LM, Hamill RW.

Brain Res Mol Brain Res. 1995 Jun;30(2):362-6.

PMID:
7637586
37.

Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients.

Richfield EK, Maguire-Zeiss KA, Cox C, Gilmore J, Voorn P.

Ann Neurol. 1995 Mar;37(3):335-43.

PMID:
7695232

Supplemental Content

Loading ...
Support Center